1-bromo-4-(bromomethyl)-2,5-difluorobenzene | 486460-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-4-(bromomethyl)-2,5-difluorobenzene
• CAS: 486460-10-0
• 化学式: C₇H₄Br₂F₂
• 分子量: 285.914
• InChiKey: NIXLFBUHPJACST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-bromo-4-(bromomethyl)-2,5-difluorobenzene 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 、 caesium carbonate 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 0.17h， 生成 tert-butyl 1-(2,5-difluoro-4-(1-methyl-1H-pyrazol-4-yl)benzyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-1'-carboxylate
  参考文献：
  名称：

  Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: The continued optimization of an MLPCN probe molecule

  摘要：

  This Letter describes the further optimization of an MLPCN probe molecule (ML137) through the introduction of 5- and 6-membered spirocycles in place of the isatin ketone. Interestingly divergent structure-activity relationships, when compared to earlier M-1 PAMs, are presented. These novel spirocycles possess improved efficacy relative to ML137, while also maintaining high selectivity for the human and rat muscarinic M-1 receptor subtype. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.017
• 作为产物：
  描述：

  4-溴-2,5-二氟苯甲酸 在 硼烷四氢呋喃络合物 、 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 66.0h， 生成 1-bromo-4-(bromomethyl)-2,5-difluorobenzene
  参考文献：
  名称：

  BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

  摘要：

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。

  公开号：

  US20150359793A1

文献信息

• [EN] SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C<br/>[FR] (BENZYL-CYANO-MÉTHYL)-AMIDES SUBSTITUÉS DE L'ACIDE 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIQUE UTILISÉS COMME INHIBITEURS DE LA CATHÉPSINE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014140075A1

  公开（公告）日：2014-09-18

  This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

  本发明涉及2-氮杂-双环[2.2.1]庚烷-3-羧酸（苄基-氰甲基）酰胺的化合物（1）及其作为组织蛋白酶C抑制剂的用途，包含该化合物的药物组合物，以及使用该化合物作为治疗和/或预防与二肽基肽酶I活性相关疾病的方法，例如呼吸系统疾病。
• BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150359793A1

  公开（公告）日：2015-12-17

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物在治疗或预防二肽基肽酶-IV酶参与的疾病中具有用途，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20160311817A1

  公开（公告）日：2016-10-27

  Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  式I的化合物或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11如本文所定义。还公开了制备这些化合物的方法以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
  申请人：——

  公开号：US20040167133A1

  公开（公告）日：2004-08-26

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，该化合物对于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病非常有用。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物预防或治疗二肽基肽酶-IV酶参与的疾病的方法。
• BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES FOR USE IN THE TREATMENT OF DIABETES TYPE II
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2226324A1

  公开（公告）日：2010-09-08

  The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inmbitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及抑制二肽基肽酶-IV酶（“DP-IV抑制剂”）的化合物，这些化合物对于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病和特别是2型糖尿病，是有用的。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的使用。